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~ Routine High Pressure Poet-Brant Dilatation did Not 
Influence Clinical Reatenoels In 8TARS 
R, Moisten, J,J, Popma, D,~, EIoim. A,J, Lan~;ky, A,~, Ablzald. J,F~ ~aucodo, 
K,M, Kent, L,F, B~tlor, A,D, Piehord. R,E, Kanlz, K, He, M,~, Loon, 
W~]~htngton Ho~ptlal C~ttt~r, W~lltngtot~ OC, USA 
Prior otodio~ I~avo uggogtod o rolational~ip between I~i011 prooouro and ovor- 
~i~od b~llooa dilation and oxco~z~ivo late lumen Io~8 alter coronary _stearin 9
To determine the clinl~al conooquonco of high prooguro dilation on late clinicol 
recurrence ~ltor optimal st~nt p~acomont, we roviowog the cflnical toured of 
1050 p0ti0nt~ onroUod in t!m Stont Antithromboit~ Regimen ~tudy ($TAR~) 
galloon:orlon/ ratlo~ wore dote'mined u~ing quantitative method8 (GM~), 
An injury ~com (l~) wo~ dolinnd o~: 0 (adji.inct PTCA pro~ooro • tO aim & 
balloon:effort/ratio ,. 1, t), f (~dlunot PTCA pmo~um :- 16 o~ balloon nrt~n/ 
retie ~ 1 t, end ~?(adiunct PTCA pro~00r0 o 10 & b~lloon:oftory ratio * 1 t), 
Mm . ~ 7~ 9 ;'6~3 ~5 .:1,95 n valo~ 
Flof~¢}e~¢.,, mm ~.~ -~, 0 2 3 O * 0 1 3 O * O 3 ,0000r 
ML0, p0sl ~ ~, 0,1 ~h, 04 3 0 ,0  5 .00001 
% ~lono~ls, post 1(1, t4 ~O * 13 ~I * 1;~ -0,0001 
13~lloon:itito~y t 3 * 0~ 1 1 ~ O 1 t t  ~ 0 1 • 0.0001 
PR[~,, ~lm 174-.30 17fi,90 177.30 0919 
"~Qnl SIIo R0v~c I~% 11% 4',= .:00001 
A muttlvanoblo model demonstrated that I;nal MLD end vo~ t si~o (OR 
0,431; p • 00001) and nor the Iniu~y score (OR = 0.90: p ~ 0,660) was 
rot(tied to laid TSR, We conclu~o Item STARS, high prossuro post.stent 
balloon dilatabon was not ~ssoclatocl with higher clinical rostenosis rates. 
4:15 
~ A  Compsrlson of the Long AVE Micro '" Slant II and 
the Palmaz-~¢hatz '*. ~tent: A SMART Trial Registry 
R. Heuser, R, Kuntz, A, Lansky, KKL. He, L Reduto, R, Bad0er, 
L,A, lannono, P Wt~itlow, R, Vlietstra. Columbia Medical Center, Phoenfx, 
AZ; Beth Israel Oeaconoss Medical Canter, Boston, MA, USA 
Background: The SMART Trial i'~ a prospective, randomized, multicenter, 
comparative thai of the AVE Micro Slant II and the Palmaz-Schatz (P/S) 
slant in do nero and rostenotic coronary lesions up Io 30 mm in lanolin. A 
non-ranclomized regzshy of patients wdh long lesions (mean = ;)2.6 ± 10.1 
mm by QCA) who received the 39 mm AVE MereStent II was also conducted, 
Methods: The data hem the 39 mm AVE Micro Stent II implantations (n 
= 160) wore compared to the data for the PIS steal implantations (n = 331) 
{rom the randomized trial, 
Results: The demographics and 6-month clinical data are: 
Demographics AVE PfS p 
Single vessel disease 8215 I%1 242 (73%) .. 0.001 
Doublo vossoI disease 48 (30%) 70 (~1%) 0,033 
Triple vessel disease 30 (19%) 10 (6%) -0001 
Pno~ MI 66 |42%) t03 (31%) 0025 
Prior CABG 23 (14%) 17 (5%) 0.001 
CCS Ill or IV 109 (68°o) 230 (69%) NS 
HTN (Rx required) 95 (59°°) 190 (58%) NS 
Hyperlip=dornia (R~ req ) 69 (43%) 101 (31%) 0 011 
D~abotos Mett~tus 4 ~ (26°°) 57 (17%) 003 
Lostontength 226 ~- 101 12 1 , 6.2 
Chnical Results A,/E P/S p 
AC.u.te p~ocedur~.t SuCCeS~ 89 4% 94.7¢:o N$ 
TLR 9.2% 81% NS 
Conclusion: In spite of a higher risk population in the AVE group, 6-month 
ett~cacy of the 39 mm AVE stent and the P/S stent were not signilicantly 
different 
4:30 
~ T h e  Wsllatont In NMIve Coronary Arlerle= (WIN) 
Multlcenter Randomized Trloh In Hospital Acute 
Results 
L, Bilodooa, T, Schlolbor, J,D, Hilton, $, Rosonblum, 6, MONa, M McIvor, 
Z, Krajc, or, B,H, Wiloon, C, 8snomhi~l, L,D, Beck, A, Podan, Montn~al Heart 
Institute, Montreal, Canada 
Thg WIN study i0 O randomized real comparing th~ c|lnicoI and ~ng!ogr~ghic 
outcome ol balloon angioplasty (BA) tO W~llstent (~T) implantati~, d~nng 
imho~pll~l ~lay and at 6 month (o!low.up~ A total el 464 pts (63 ~ 11 yr, 
7~% male) wet0 randomitsd to either gA (~5)  or ST I_9.L~9) Eighty thrw 
percent of pit  h~d unstable angina and 18% pro~onLed a fOb, LenDIng Ion=on, 
Target Iooi0n typed w0r0 ~6% 01, 41% B~, ~nd 10% C (15% g~la~oitv~li; 
vessels worn': ~% LAD, ~6% CX, and 48% RCA, In the I~A 0reaP, ~5~ ot 
pt~ received a boil Out slant ac¢omJn 9 to stnn!!]ont prowl cnte,~, Pmce~:~r~t 
ao~;~so w-~ 9~),~% in the ST group and 97~8% in tire BA ~coo~J~n~l to the 
aetua! proto¢;ol, Abrupt and suba~mto closure wore ~00fv~-J in 3 a~J ~ pIs 
in the ~T .Proap cqmpar0d tq 4 and 3 pt~ tn !hq E~A g!oup, !Osp~f!veJy (p = 
N~;), 
Conclusi_cm: Acate_ly the W~!lste~nt ts ao otte~livo as baliox)n ~np¢oplasly 
The 6.month c!int(;al follow,up will b~ prose~ntod. 
In.Hospital EvOnts 
EiT m ~- ~99) 0A in ~- ~351 
n (%) n (%i p 
30 d~y de~lh I (Q 4l 1 t0 4t 0 99 
Em GAnG t ta4t ~ (O 0) 0 58 
O MI 0 tO0) t tO 4t 032 
NO MI 16 (70) 12 t5 1 ) a 40 
CVA I (0 4) 0 (0 at 0 31 
CAOG 1 t04) ~ (09) 058 
RO PTCA 6 (~6) 2 to 9t 0 14 
Combined ,~ 19 6t 1315 5) 0 10 
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~ A  MulUcenter Randomized Trial Comparing Five 
Different "l~pes of Slotted-Tube Slents 
J. Hausleiter, J. Dirschinger, H. Sehuhlen. W. Giehd I , H. Walter, J. Pache. 
S. Elezi, A. Wehinger. P Boekstegem ~ . G. Steinbeck ~ , A. Sch0mlg 
Deutsches Herzzentrum & Klinikum rechts dot tsar, TUM. Germany: 
~ Khnikum GreBhadem. LMU: Munich. Germany 
Background: The impact o1 diff,~ront stent designs on procedural success 
and maim adverse cardiac events (MACE) is not known. 
Methods: We conducted a mult~center randomized tnal companng 5 dd- 
ferent commercially available slotted-tube stems. Four stent types tPalmaz- 
Schatz (PS). Jormson & Johnson; NIR, Boston Scienldic: Pure A: Devon 
Medical; ID, Inflow Dynamics) wele implanted as bare stents hand-mounted 
on standard balloon catheters. The Multilink slant tAGS) was used with its 
stent delivery system (SOS). From May 96 until May 97, 1126 patients were 
randomized, By August 97, complete 30-days fellow-up data are available in 
90.5°-0. 
Results: On intention.to.treat basis, overall success rate without MACE at 
30-days follow-up was 946% with PS, 94.7=..o with NIR, 96.6% with Pure A. 
94.3% with ID and 95.6% with ACS. However, in 14% this was only achieved 
alter deploying slants o! other type. 30-day success without MACE, and 
without deployment of stent types other than randomized, was achieved in 
85.9% of PS, 90.3% of NIR, 90.7% Of Pure A, 93.3% of ID and 64.2=0 of 
ACS. Based on the actually implanted steal type, the occ!usion rates were 
1.2% for PS, 2.2°.0 for NIR, 1.8% for Pura A, 2.0% for ID. end 1.4% for ACS 
Conclusions: These preliminan/ data suggest significant differences ;n 
pr- lural success rates, predominantly reflecting differences in trackabtlity. 
t or. MACE and occlusion rates are not significantly different between 
( .~ent typr=s. 
5:0O 
[ -~-~ Late Quantitative Angiographic Results After NIR 
Stent Use: Results From the NIRVANA Randomized 
Trial and Registries 
A.J. Lansky. J.J. Popma, R. Mehran, J.F. Saucedo, A.S. Abizaid, 
C O'Shaughnessy, J.B. HermiUer. D. Cutlip. i4.E. Kuntz, D.S. Bairn, 
MB Leon. Washington Hospital Center, Washington DC, USA 
The NIR Steal is a novel, stainless steel, continuous weave multiceitular slant 
with 7 (2.5-3,5 mm stents) or 9 (3.5-4.0 mm steals) adaptive cells that confer 
unique flexibility when unexpanded and support and vessel contormability 
when expanded. The clinical safety and efficacy of the NIR stent in de hove 
